XML 42 R32.htm IDEA: XBRL DOCUMENT v3.25.0.1
Basis of Presentation and Summary of Significant Accounting Policies - Additional Information (Details)
 12 Months Ended
Jan. 01, 2024
USD ($)
Dec. 31, 2024
USD ($)
Segment
Conversion of Stock [Line Items]    
Number of operating segments | Segment   1
Accrued clinical trial expenses   $ 4,400,000
Payment terms   Payment terms and conditions vary by contracts, although terms generally include a requirement of payment within 30 to 45 days after invoice.
Accounting Standards Update [Extensible Enumeration]   ASU 2020-06
ASU 2020-06    
Conversion of Stock [Line Items]    
Change in Accounting Principle, Accounting Standards Update, Adopted [true false]   true
Change in Accounting Principle, Accounting Standards Update, Adoption Date   Jan. 01, 2024
Accounting Standards Update [Extensible Enumeration]   us-gaap:AccountingStandardsUpdate202006RetrospectiveMember
ASU 2023-07    
Conversion of Stock [Line Items]    
Change in Accounting Principle, Accounting Standards Update, Adopted [true false]   true
Cumulative Effect, Period of Adoption, Adjustment | Series A Convertible Preferred Stock    
Conversion of Stock [Line Items]    
Temporary equity, dividends, adjustment $ 793,000